71592-44-4

Basic information

• Product Name: hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one
• Synonyms: hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one;3-(3-hydroxyphenyl)-1-Methylazepan-2-one
• CAS NO: 71592-44-4
• Molecular Formula: C₁₃H₁₇NO₂
• Molecular Weight: 219.27958
• EINECS: 275-650-3
• Mol File: 71592-44-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 192-193℃
• Boiling Point: 413.983 °C at 760 mmHg
• Flash Point: 204.17 °C
• Appearance: /
• Density: 1.128
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: 2-8°C
• CAS DataBase Reference: hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one(71592-44-4)
• EPA Substance Registry System: hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one(71592-44-4)

Safety Data

• Hazardous Substances Data: 71592-44-4(Hazardous Substances Data)

Usage

General Description

Hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one, also known as trimebutine, is a chemical compound with pharmacological properties. It is used as a spasmolytic agent, mainly for the treatment of irritable bowel syndrome and other gastrointestinal disorders. Trimebutine works by reducing muscle spasms in the digestive tract, which helps to alleviate symptoms such as abdominal pain, bloating, and discomfort. It also has a mild analgesic effect, contributing to its efficacy in pain relief. Trimebutine is generally well-tolerated and has minimal adverse effects, making it a popular choice for the management of gastrointestinal conditions.

InChI:InChI=1/C13H17NO2/c1-14-8-3-2-7-12(13(14)16)10-5-4-6-11(15)9-10/h4-6,9,12,15H,2-3,7-8H2,1H3

Upstream product

• 77801-59-3 o-chlorotriphenylsilyloxybenzene 
• 105-60-2 caprolactam 
• 766-51-8 2-Chloroanisole 
• 2556-73-2 1-methyl-2-azepanone 
• 71592-43-3 hexahydro-3-(3-methoxyphenyl)-1-methyl-2H-azepin-2-one 
• 87887-08-9 3-(2-bromo-3-oxocyclohex-1-enyl)hexahydro-1-methylazepin-2-one 
• 87887-07-8 3-(2-chloro-3-oxocyclohex-1-enyl)hexahydro-1-methylazepin-2-one 
• 71556-70-2 hexahydro-1-methyl-3-(3-oxocyclohexen-1-yl)<2H>azepin-2-one 

Downstream Products

• 76778-47-7 hexahydro-3-(6-bromo-3-hydroxyphenyl)-1-methyl<2H>azepin-2-one 
• 76778-48-8 hexahydro-3-(4,6-dibromo-3-hydroxyphenyl)-1-methyl<2H>azepin-2-one 
• 27180-92-3 meptazinol hydrobromide 
• 71556-72-4 3-Ethyl-hexahydro-3-(3-methoxyphenyl)-1-methyl-2H-azepin-2-one 
• 59263-76-2 Meptazinol hydrochloride 
• 71556-73-5 3-ethylhexahydro-3-(3-methoxyphenyl)-1-methyl<1H>azepine 
• 54340-58-8 3-(3-ethyl-1-methyl-1H-hexahydroazepin-3-yl)phenol 
• 71592-43-3 hexahydro-3-(3-methoxyphenyl)-1-methyl-2H-azepin-2-one 
• 71556-74-6 3-Ethyl-hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one 

Relevant articles and documents

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents

A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.

2-Bromo-3-methoxycyclohex-2-enone, a New Reagent for the α-Arylation of Lactams

We report efficient syntheses of 2-bromo and 2-chloro-3-methoxycyclohex-2-enone and their use as m-hydroxyphenyl cation synthons for the α-arylation of lactams.The sequence has been used to synthesize the analgesic drug meptazinol.

Process for preparing hexahydroazepine, piperidine and pyrrolidine derivatives

2-Oxo-hexahydroazepine, -piperidine or pyrrolidines of formula STR1 wherein n is 2,3 or 4, R is hydrogen, lower alkyl, aryl(lower)alkyl, loweralkenylmethyl or cycloalkylmethyl, R1 is hydrogen or lower alkyl and R2 is hydrogen, lower alkyl or aryl(lower)alkyl are prepared by a novel process involving reaction of an anion of a lactam of formula STR2 where R3 is lower alkyl, aryl(lower)alkyl, trialkyl-, triaryl- or triarylalkyl-silyl with a benzyne of formula STR3 where R4 is lower alkyl, aryl(lower)alkyl or trialkyl-, triaryl- or triarylalkyl-silyl. The products are useful as intermediates for preparing pharmacologically active 2-unsubstituted -hexahydroazepine, -piperidine and pyrrolidine derivatives.